Why unbelievable? The problem of Aegerion is just the CEO. Juxtapid is superior to Kynamro, and the story of the partial lipodystrophy is a joke. They base the indication on some old data showing that in some family with abnormal capo CIII you also find some form of lipodystrophy. Is this enough?
As a specialist in the area, I see lots of statin intolerance. But why should you manage this with a very costly injectable drug, versus a simple oral, most likely, low cost agent? In addition some of the cognitive effects of PCSK9 antagonists are worrisome. Don't forget that PCSK9 is a brain enzyme